|
1
|
World Health Organization. Available
online at: https://covid19.who.int/ (Accesed on
15th January 2023).
|
|
2
|
Yadaiah KB, Shah C, Cheryala V, Gali JH,
Kishore SK, Kumar R, Gunturu H and Sushmita G: Effect of SARS-CoV-2
on glycemic control in post-COVID-19 diabetic patients. J Family
Med Prim Care. 11:6243–6249. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Carsana L, Sonzogni A, Nasr A, Rossi RS,
Pellegrinelli A, Zerbi P, Rech R, Colombo R, Antinori S, Corbellino
M, et al: Pulmonary post-mortem findings in a series of COVID-19
cases from northern Italy: A two-centre descriptive study. Lancet
Infect Dis. 20:1135–1140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Apicella M, Campopiano MC, Mantuano M,
Mazoni L, Coppelli A and Del Prato S: COVID-19 in people with
diabetes: Understanding the reasons for worse outcomes. Lancet
Diabetes Endocrinol. 8:782–792. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Calvisi SL, Ramirez GA, Scavini M, Da Prat
V, Di Lucca G, Laurenzi A, Gallina G, Cavallo L, Borio G, Farolfi
F, et al: Thromboembolism risk among patients with diabetes/stress
hyperglycemia and COVID-19. Metabolism. 123(154845)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pitocco D, Viti L, Tartaglione L, Di Leo
M, Rizzo GE, Manto A, Rizzi A, Caputo S and Pontecorvi A: Diabetes
and severity of COVID-19: What is the link? Med Hypotheses.
143(109923)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wijaya I, Andhika R and Huang I:
Hypercoagulable state in COVID-19 with diabetes mellitus and
obesity: Is therapeutic-dose or higher-dose anticoagulant
thromboprophylaxis necessary? Diabetes Metab Syndr. 14:1241–1242.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
van den Oever IA, Raterman HG, Nurmohamed
MT and Simsek S: Endothelial dysfunction, inflammation, and
apoptosis in diabetes mellitus. Mediators Inflamm.
2010(792393)2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Haller H: The endothelium and the
pathogenesis of chronic vascular diseases: The protective role of
calcium antagonists. In: Lüscher TF (eds). The Endothelium in
Cardiovascular Disease. Springer, Berlin, Heidelberg, pp97-107,
1995.
|
|
10
|
Calles-Escandon J and Cipolla M: Diabetes
and endothelial dysfunction: A clinical perspective. Endocr Rev.
22:36–52. 2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Varga Z, Flammer AJ, Steiger P, Haberecker
M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka
F and Moch H: Endothelial cell infection and endotheliitis in
COVID-19. Lancet. 395:1417–1418. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pelle MC, Zaffina I, Lucà S, Forte V,
Trapanese V, Melina M, Giofrè F and Arturi F: Endothelial
dysfunction in COVID-19: Potential mechanisms and possible
therapeutic options. Life (Basel). 12(1605)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Higuchi S, Ohtsu H, Suzuki H, Shirai H,
Frank GD and Eguchi S: Angiotensin II signal transduction through
the AT1 receptor: Novel insights into mechanisms and
pathophysiology. Clin Sci (Lond). 112:417–428. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Del Turco S, Vianello A, Ragusa R, Caselli
C and Basta G: COVID-19 and cardiovascular consequences: Is the
endothelial dysfunction the hardest challenge? Thromb Res.
196:143–151. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Coman AE, Ceasovschih A, Petroaie AD, Popa
E, Lionte C, Bologa C, Haliga RE, Cosmescu A, Slănină AM, Bacușcă
AI, et al: The significance of low magnesium levels in COVID-19
patients. Medicina (Kaunas). 59(279)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bonaventura A, Vecchié A, Dagna L,
Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F,
Massberg S, Levi M and Abbate A: Endothelial dysfunction and
immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev
Immunol. 21:319–329. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jackson SP, Darbousset R and Schoenwaelder
SM: Thromboinflammation: Challenges of therapeutically targeting
coagulation and other host defense mechanisms. Blood. 133:906–918.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Foley JH and Conway EM: Cross talk
pathways between coagulation and inflammation. Circ Res.
118:1392–1408. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Margetic S: Inflammation and haemostasis.
Biochem Med (Zagreb). 22:49–62. 2012.PubMed/NCBI
|
|
20
|
Chanchal S, Mishra A, Singh MK and Ashraf
MZ: Understanding inflammatory responses in the manifestation of
prothrombotic phenotypes. Front Cell Dev Biol. 8(73)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Páramo JA: Inflammatory response in
relation to COVID-19 and other prothrombotic phenotypes. Reumatol
Clin (Engl Ed). 18:1–4. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cabrera-Rivera GL, Madera-Sandoval RL,
León-Pedroza JI, Ferat-Osorio E, Salazar-Rios E, Hernández-Aceves
JA, Guadarrama-Aranda U, López-Macías C, Wong-Baeza I and
Arriaga-Pizano LA: Increased TNF-α production in response to IL-6
in patients with systemic inflammation without infection. Clin Exp
Immunol. 209:225–235. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Copaescu A, Smibert O, Gibson A, Phillips
EJ and Trubiano JA: The role of IL-6 and other mediators in the
cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin
Immunol. 146:518–534.e1. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Faraj SS and Jalal PJ: IL1β, IL-6, and
TNF-α cytokines cooperate to modulate a complicated medical
condition among COVID-19 patients: Case-control study. Ann Med Surg
(Lond). 85:2291–2297. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Norooznezhad AH and Mansouri K:
Endothelial cell dysfunction, coagulation, and angiogenesis in
coronavirus disease 2019 (COVID-19). Microvasc Res.
137(104188)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cohen T, Nahari D, Cerem LW, Neufeld G and
Levi BZ: Interleukin 6 induces the expression of vascular
endothelial growth factor. J Biol Chem. 271:736–741.
1996.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tan LY, Komarasamy TV and Rmt
Balasubramaniam V: Hyperinflammatory immune response and COVID-19:
A double edged sword. Front Immunol. 12(742941)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian
C, Qin R, Wang H, Shen Y, Du K, et al: Diabetes is a risk factor
for the progression and prognosis of COVID-19. Diabetes Metab Res
Rev. 36(e3319)2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
29
|
Kito K, Tanabe K, Sakata K, Fukuoka N,
Nagase K, Iida M and Iida H: Endothelium-dependent vasodilation in
the cerebral arterioles of rats deteriorates during acute
hyperglycemia and then is restored by reducing the glucose level. J
Anesth. 32:531–538. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Meerarani P, Moreno PR, Cimmino G and
Badimon JJ: Atherothrombosis: Role of tissue factor; link between
diabetes, obesity and inflammation. Indian J Exp Biol. 45:103–110.
2007.PubMed/NCBI
|
|
31
|
Verkleij CJ, Bruijn RE, Meesters EW,
Gerdes VE, Meijers JC and Marx PF: The hemostatic system in
patients with type 2 diabetes with and without cardiovascular
disease. Clin Appl Thromb Hemost. 17:E57–E63. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Thögersen AM, Jansson JH, Boman K, Nilsson
TK, Weinehall L, Huhtasaari F and Hallmans G: High plasminogen
activator inhibitor and tissue plasminogen activator levels in
plasma precede a first acute myocardial infarction in both men and
women: Evidence for the fibrinolytic system as an independent
primary risk factor. Circulation. 98:2241–2247. 1998.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Iwasaki Y, Kambayashi M, Asai M, Yoshida
M, Nigawara T and Hashimoto K: High glucose alone, as well as in
combination with proinflammatory cytokines, stimulates nuclear
factor kappa-B-mediated transcription in hepatocytes in vitro. J
Diabetes Complications. 21:56–62. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Rojas A, Lindner C, Gonzàlez I and Morales
MA: Advanced-glycation end-products axis: A contributor to the risk
of severe illness from COVID-19 in diabetes patients. World J
Diabetes. 12:590–602. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Manigrasso MB, Juranek J, Ramasamy R and
Schmidt AM: Unlocking the biology of RAGE in diabetic microvascular
complications. Trends Endocrinol Metab. 25:15–22. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ramasamy R, Yan SF and Schmidt AM: The
diverse ligand repertoire of the receptor for advanced glycation
endproducts and pathways to the complications of diabetes. Vascul
Pharmacol. 57:160–167. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Audard J, Godet T, Blondonnet R, Joffredo
JB, Paquette B, Belville C, Lavergne M, Gross C, Pasteur J, Bouvier
D, et al: Inhibition of the receptor for advanced glycation
end-products in acute respiratory distress syndrome: A randomised
laboratory trial in piglets. Sci Rep. 9(9227)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Blondonnet R, Audard J, Belville C,
Clairefond G, Lutz J, Bouvier D, Roszyk L, Gross C, Lavergne M,
Fournet M, et al: RAGE inhibition reduces acute lung injury in
mice. Sci Rep. 7(7208)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Vaidyula VR, Rao AK, Mozzoli M, Homko C,
Cheung P and Boden G: Effects of hyperglycemia and hyperinsulinemia
on circulating tissue factor procoagulant activity and platelet
CD40 ligand. Diabetes. 55:202–208. 2006.PubMed/NCBI
|
|
40
|
Stegenga ME, van der Crabben SN, Dessing
MC, Pater JM, van den Pangaart PS, de Vos AF, Tanck MW, Roos D,
Sauerwein HP and van der Poll T: Effect of acute hyperglycaemia
and/or hyperinsulinaemia on proinflammatory gene expression,
cytokine production and neutrophil function in humans. Diabet Med.
25:157–164. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dunn EJ, Philippou H, Ariëns RA and Grant
PJ: Molecular mechanisms involved in the resistance of fibrin to
clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Diabetologia. 49:1071–1080. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Dayer MR, Mard-Soltani M, Dayer MS and
Alavi SM: Causality relationships between coagulation factors in
type 2 diabetes mellitus: Path analysis approach. Med J Islam Repub
Iran. 28(59)2014.PubMed/NCBI
|
|
43
|
Boden G and Rao AK: Effects of
hyperglycemia and hyperinsulinemia on the tissue factor pathway of
blood coagulation. Curr Diab Rep. 7:223–227. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Neergaard-Petersen S, Hvas AM, Kristensen
SD, Grove EL, Larsen SB, Phoenix F, Kurdee Z, Grant PJ and Ajjan
RA: The influence of type 2 diabetes on fibrin clot properties in
patients with coronary artery disease. Thromb Haemost.
112:1142–1150. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Abdul Razak MK and Sultan AA: The
importance of measurement of plasma fibrinogen level among patients
with type-2 diabetes mellitus. Diabetes Metab Syndr. 13:1151–1158.
2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pieters M, van Zyl DG, Rheeder P, Jerling
JC, Loots du T, van der Westhuizen FH, Gottsche LT and Weisel JW:
Glycation of fibrinogen in uncontrolled diabetic patients and the
effects of glycaemic control on fibrinogen glycation. Thromb Res.
120:439–446. 2007.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tang N, Li D, Wang X and Sun Z: Abnormal
coagulation parameters are associated with poor prognosis in
patients with novel coronavirus pneumonia. J Thromb Haemost.
18:844–847. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Panigada M, Bottino N, Tagliabue P,
Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F
and Tripodi A: Hypercoagulability of COVID-19 patients in intensive
care unit: A report of thromboelastography findings and other
parameters of hemostasis. J Thromb Haemost. 18:1738–1742.
2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Mir N, D'Amico A, Dasher J, Tolwani A and
Valentine V: Understanding the andromeda strain-the role of
cytokine release, coagulopathy and antithrombin III in SARS-CoV2
critical illness. Blood Rev. 45(100731)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Goshua G, Pine AB, Meizlish ML, Chang CH,
Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, et al:
Endotheliopathy in COVID-19-associated coagulopathy: Evidence from
a single-centre, cross-sectional study. Lancet Haematol.
7:e575–e582. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B,
Zhang J and Lu J: Coagulation dysfunction is associated with
severity of COVID-19: A meta-analysis. J Med Virol. 93:962–972.
2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Thachil J, Tang N, Gando S, Falanga A,
Cattaneo M, Levi M, Clark C and Iba T: ISTH interim guidance on
recognition and management of coagulopathy in COVID-19. J Thromb
Haemost. 18:1023–1026. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Li G, Chen Z, Lv Z, Li H, Chang D and Lu
J: Diabetes mellitus and COVID-19: Associations and possible
mechanisms. Int J Endocrinol. 2021(7394378)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Li H, Chen S, Wang S, Yang S, Cao W, Liu
S, Song Y, Li X, Li Z, Li R, et al: Elevated D-dimer and adverse
in-hospital outcomes in COVID-19 patients and synergism with
hyperglycemia. Infect Drug Resist. 15:3683–3691. 2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Mishra Y, Pathak BK, Mohakuda SS, Tilak
TVSVGK, Sen S, P H, Singh R and Singh AR: Relation of D-dimer
levels of COVID-19 patients with diabetes mellitus. Diabetes Metab
Syndr. 14:1927–1930. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Sindi AA, Tashkandi WA, Jastaniah MW,
Bashanfar MA, Fakhri AF, Alsallum FS, Alguydi HB, Elhazmi A,
Al-Khatib TA, Alawi MM and Abushoshah I: Impact of diabetes
mellitus and co-morbidities on mortality in patients with COVID-19:
A single-center retrospective study. Saudi Med J. 44:67–73.
2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
von Meijenfeldt FA, Havervall S,
Adelmeijer J, Lundström A, Rudberg AS, Magnusson M, Mackman N,
Thalin C and Lisman T: Prothrombotic changes in patients with
COVID-19 are associated with disease severity and mortality. Res
Pract Thromb Haemost. 5:132–141. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Miri C, Charii H, Bouazzaoui MA, Laouan
Brem F, Boulouiz S, Abda N, Kouismi H, Bazid Z, Ismaili N and El
Ouafi N: D-dimer level and diabetes in the COVID-19 infection. Clin
Appl Thromb Hemost. 27(10760296211045902)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Novida H, Soelistyo SA, Cahyani C, Siagian
N, Hadi U and Pranoto A: Factors associated with disease severity
of COVID-19 in patients with type 2 diabetes mellitus. Biomed Rep.
18(8)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Bradley BT, Maioli H, Johnston R, Chaudhry
I, Fink SL, Xu H, Najafian B, Deutsch G, Lacy JM, Williams T, et
al: Histopathology and ultrastructural findings of fatal COVID-19
infections in Washington State: A case series. Lancet. 396:320–332.
2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Whyte MB, Vas P, Heiss C and Feher MD: The
contribution of diabetic micro-angiopathy to adverse outcomes in
COVID-19. Diabetes Res Clin Pract. 164(108217)2020.PubMed/NCBI View Article : Google Scholar
|
